MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GUPTA, S. K.
Right arrow Articles by TRIGGLE, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GUPTA, S. K.
Right arrow Articles by TRIGGLE, D. J.

Molecular Pharmacology, Vol 12, 1019-1026, Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics

Mechanism of Action of Benzilylcholine Mustard at the Muscarinic Receptor

SURENDRA K. GUPTA 1, JOHN F. MORAN 1, and DAVID J. TRIGGLE 1

1 Departments of Biochemistry and Biochemical Pharmacology, Schools of Medicine, Dentistry, and Pharmacy, State University of New York at Buffalo, Buffalo, New York 14214

The irreversible antagonism exerted by benzilylcholine mustard (BCM) on acetylcholine-induced contractions of the isolated guinea pig ileum can best be characterized by multiple sites of alkylation. BCM (50 µM, for 15 min) completely abolishes the response to acetylcholine, but the maximum responsiveness of the tissue recovers with time according to a first-order process (t1/2 of 45 min). Recovery of response is correlated with a first-order loss of tritium from tissues blocked with [3H]BCM (t1/2 of 38.9 min). The rightward shift of the dose-response curves observed after recovery of maximum response (acetylcholine dose ratio = 390) is stable over 8 hr, although the dose ratio would be expected to return toward control values if the receptor reserve model was applicable in this tissue. The data can best be interpreted on the basis that BCM alkylates two sites at the muscarinic receptor: an allosteric site which stabilizes an inactive form of the receptor, resulting in an apparent decrease in affinity for the agonist, and a second site which is postulated to be the agonist recognition site proper. Alkylation of the second site results in decreased maximum response.

Submitted on January 14, 1976
Accepted on July 5, 1976







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics